anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Preparations of technical and therapeutic application are obtained by melting sulphur with sugar and starch in the presence of air and suspending the cooled product in water; partial concentration yields a liquid containing sulphur oils and suspended sulphur, whilst concentration almost to completion gives a residue from which sulphur oils can be pressed out.  The Specification as open to inspection under Sect. 91 (3) (a) describes also the replacement of the starch by other organic substances such as resins and states that the separation of the products is accelerated by the addition of a ferment, e.g. yeast. This subject-matter does not appear in the Specification as accepted.ALSO:Preparations of technical and therapeutic application are obtained by melting sulphur with sugar and starch in the presence of air and suspending the cooled product in water; partial concentration yields a liquid containing sulphur oils and suspended sulphur, whilst concentration almost to completion gives a residue from which sulphur oils can be pressed out.  The properties of the sulphur oils are described.  The Specification as open to inspection under Sect. 91 (3) (a) describes also the replacement of the starch by other organic substances such as resins, and states that the separation of the products is accelerated by the addition of a ferment, e.g. yeast. The products, which may be extracted with alcohol or ether to obtain the organic sulphur compounds, comprise a mixture of the latter with finely-divided sulphur and are stated to be useful for internal or external medicinal treatment, as vermin-destroying agents, and in the manufacture of cosmetics, ointments and bathing preparations.  This subject-matter does not appear in the Specification as accepted.ALSO:Preparations of therapeutic application are obtained by melting sulphur with sugar and starch in the presence of air and suspending the cooled product in water; partial concentration yields a liquid containing sulphur oils and suspended sulphur, whilst concentration almost the completion gives a residue from which sulphur oils can be pressed out.  The Specification as open to inspection under Sect. 91 (3) (a) describes also the replacement of the starch by other organic substances such as resins, and states that the separation of the products is accelerated by the addition of a ferment, e.g. yeast. The products may be used for internal or external medicinal treatment, as vermin-destroying agents, and in the manufacture of cosmetics, ointments, soaps, and bathing preparations. This subject-matter does not appear in the Specification as accepted.
Temporal alignment is often viewed as the most essential cue the brain can use to integrate information from across sensory modalities. However, the importance of conscious perception of synchrony to multisensory integration is a controversial topic. Conversely, the influence of cross-modal incongruence of higher level stimulus features such as phonetics on temporal processing is poorly understood. To explore the nuances of this relationship between temporal processing and multisensory integration, we presented 101 participants (ranging from 19 to 73 years of age) with stimuli designed to elicit the McGurk/MacDonald illusion (either matched or mismatched pairs of phonemes and visemes) with varying degrees of stimulus onset asynchrony between the visual and auditory streams. We asked them to indicate which syllable they perceived and whether the video and audio were synchronized on each trial. We found that participants often experienced the illusion despite not perceiving the stimuli as synchronous, and the same phonetic incongruence that produced the illusion also led to significant interference in simultaneity judgments. These findings challenge the longstanding assumption that perception of synchrony is a prerequisite to multisensory integration, support a more flexible view of multisensory integration, and suggest a complex, reciprocal relationship between temporal and multisensory processing.
Left atrial appendage occlusion devices (LAAO) are a feasible alternative for non-valvular atrial fibrillation (AF) patients at high risk of thromboembolic stroke and contraindication to antithrombotic therapies. However, optimal LAAO device configurations (i.e., size, type, location) remain unstandardized due to the large anatomical variability of the left atrial appendage (LAA) morphology, leading to a 4-6% incidence of device-related thrombus (DRT). In-silico simulations have the potential to assess DRT risk and identify the key factors, such as suboptimal device positioning. This work presents fluid simulation results computed on 20 patient-specific left atrial geometries, analysing different commercially available LAAO occluders, including plug-type and pacifier-type devices. In addition, we explored two distinct device positions: 1) the real post-LAAO intervention configuration derived from follow-up imaging; and 2) one covering the pulmonary ridge if it was not achieved during the implantation (13 out of 20). In total, 33 different configurations were analysed. In-silico indices indicating high risk of DRT (e.g., low blood flow velocities and flow complexity around the device) were combined with particle deposition analysis based on a discrete phase model. The obtained results revealed that covering the pulmonary ridge with the LAAO device may be one of the key factors to prevent DRT, resulting in higher velocities and reduced flow recirculations (e.g., mean velocities of 0.183 ± 0.12 m/s and 0.236 ± 0.16 m/s for uncovered versus covered positions in DRT patients). Moreover, disk-based devices exhibited enhanced adaptability to various LAA morphologies and, generally, demonstrated a lower risk of abnormal events after LAAO implantation.
Group 1:Patients undergo mastectomy or Breast conserving surgery after radiotherapy Group 2:Patients receive boost in the area of residual breast mass and regional lymph node. A total dose of 66Gy will be given.
STUDY OBJECTIVES: Sleep quality is important during childhood and adolescence. Given the high prevalence of pain in children/youth with cerebral palsy, we aimed to measure the association between short-term pain trajectories and sleep disturbance in these individuals.
METHODS: We accrued the cohort between November 2019 and October 2020 and recruited children/youth who (1) were 8-18 years old; (2) had cerebral palsy with any Gross Motor Function Classification System level; and (3) could self-report pain and sleep disturbance. We collected self-reported baseline and weekly follow-up data using electronic questionnaires completed every week for 5 weeks. Sleep disturbance at 5 weeks was the primary outcome (pediatric Patient-Reported Outcomes Measurement Information System short form, v1.0-4a). We used general linear regression to assess the association between pain intensity trajectory group and sleep disturbance controlling for confounders.
RESULTS: A total of 190 individuals were eligible; 102 were enrolled and 89 were included in our final analysis. Pain trajectory groups had estimated crude mean sleep disturbance scores at 5 weeks ranging from 56.0 (95% confidence interval, 51.8, 60.8) to 61.8 (55.7, 67.9). Compared to those with stable, no/very mild pain, those in the stable, high-pain group had the greatest sleep disturbance (adjusted β = 5.7; 95% confidence interval, 1.2, 10.2).
CONCLUSIONS: Irrespective of pain trajectory, children and youth with cerebral palsy reported sleep disturbances. Those with a stable, high pain intensity in the previous 5 weeks reported the greatest sleep disturbance. The results highlight the importance of considering pain trajectories and their impact on sleep in children with cerebral palsy.
CITATION: Shearer HM, Côté P, Hogg-Johnson S, Fehlings DL. A good night's sleep: pain trajectories and sleep disturbance in children with cerebral palsy. J Clin Sleep Med. 2024;20(5):719-726.
The present invention is directed to one or more macromolecules in a lipid vesicle oral formulation which targets intracellular receptors, in particular for peptides, proteins, nucleic acids and mixtures thereof, optionally in combination with small molecules. The invention encapsulates said macromolecules in a neutral, lipid vesicle comprised of one or more cholesteryl esters. Unique properties of macromolecules encapsulated in said vesicles include high oral bioavailability, defined herein as in at least 50%, i.e., often in excess of 50% on the basis of oral to parenteral AUC. Non-limiting examples are provided, for large hydrophilic molecules such as peptides, proteins and nucleic acids which heretofore have been very poorly absorbed by the mammalian intestine. In prior art, said molecules are generally less than 25% bioavailable, even with protective coatings and optionally absorption enhancing component substances in the formulation. An additional feature of the present invention is high tissue concentrations after oral use, a result of rapid uptake of cholestosomes delivered by chlimicrons to body cells. A preferred embodiment is disclosed for use in the immunotherapy of cancer.
The present invention pertains to novel treatments for cancer diseases. Treatment of cancers with nucleoside analogs (NA), which specifically inhibit rapidly dividing cells, may face preexisting NA resistance or development of resistant cancer cells resulting in poor clinical prognosis. Treatment of cancers with oncolytic herpes simplex viruses (HSV) may face preexisting resistance or development of resistant cancer cells resulting in poor clinical prognosis. The invention overcomes chemotherapy resistance or resistance to oncolytic HSV by providing methods for detecting the resistance in a cancer disease based on the expression of SAM domain and HD domain-containing protein 1 (SAMHD1) in cancer cells. Furthermore provided are treatment options addressing the chemotherapy resistance such as a combination of a SAMHD1 inhibitor with a NA. Moreover, provided are treatment options addressing the resistance to oncolytic HSV such as a combination of a SAMHD1 inhibitor or depletion of SAMHD1 with an oncolytic HSV. The combination in some embodiments may furthermore include an inhibitor of CTP-synthetase. The invention provides new medicines and companion diagnostics supporting clinical treatment decisions.
Data are limited regarding gastrointestinal motility disturbance in disorders of gut-brain interaction (DGBI). This study aimed to characterize antroduodenal motor alterations in patients with high-resolution antroduodenal manometry (HR-ADM). HR-ADM was performed in patients with severe DGBI and compared with healthy volunteers (HV). HR-ADM used a commercially available probe composed of 36 electronic sensors spaced 1 cm apart and positioned across the pylorus. Antral and duodenal motor high-resolution profiles were analyzed, based on the frequency, amplitude, and contractile integral/sensor (CI/s) calculated for each phase of the migrating motor complex (MMC). Eighteen HV and 64 patients were investigated, 10 with irritable bowel syndrome (IBS), 24 with functional dyspepsia (FD), 15 with overlap IBS-FD, and 15 with other DGBI. Compared with HV, patients had a lower frequency of phase II duodenal contractions (27 vs. 51 per hour; P = 0.002) and a lower duodenal phase II contraction amplitude (70 vs. 100 mmHg; P = 0.01), resulting in a lower CI/s of phase II (833 vs. 1,901 mmHg·cm·s; P < 0.001) in the duodenum. In addition, the frequency of phase II propagated antroduodenal contractions was lower (5 vs. 11 per hour; P < 0.001) in patients compared with HV. Interestingly, the antral CI/s of phase III was decreased in FD patients but not in IBS patients. Patients with severe DGBI display alterations in antral and intestinal motility assessed by commercially available HR-ADM. Whether these alterations may explain symptom profiles in such patients remains to be confirmed (NCT04918329 and NCT01519180).NEW & NOTEWORTHY Gastrointestinal dysmotility has been assessed poorly in disorders of gut-brain interaction (DGBI), especially with high-resolution antroduodenal manometry. Plots of DGBI patients showed lower duodenal contractions during phase II regarding amplitude, frequency, and contractile integral/sensor (CI/s) compared with healthy volunteers. A lower frequency of propagated antroduodenal contractions was also reported. Finally, antral CI/s was lower in patients with functional dyspepsia during phase III. Further studies are needed to assess the clinical significance of these alterations.
An ultrasonic system and a method for forming an ultrasonic image data are provided to reduce a cost by replacing special-purpose hardware and software like a beam forming ASIC(Application Specific Integrated Circuit) with a multiprocessor. A transducer(110) receives an ultrasonic reflection signal from an object, and forms a receiving signal according to a channel. A beam former(130A) synthesizes the receiving signal according to the channel, and forms a synthesized signal. A signal assigning part(120) divides the synthesized signal into a dividing signal. A multiprocessor(130B) individually processes the dividing signal, and forms a dividing image data. An image data synthesizing part(140) synthesizes the dividing image data, and forms an image data. An image data processing part(150) forms a pixel data based on the image data. A display part(160) displays an ultrasonic image on a screen based on the pixel data.
A one-step permanent waving compsn. (A) comprises (a) as main component a (hydrogen)sulphide or mercapto cpd. (I); (b) an accelerator for air oxidn.; (c) at least alkali to give pH 8-11; (e) an aq. carrier for all the components. Pref. (I) is an alkali metal or ammonium (hydrogen)sulphide or thioglycolate; (II) is an alkali metal or ammonium sulphite; and component (b) is at least one of hexamethylene tetramine, iodine, bromine, or alkali metal or ammonium bromide or iodide. The compsn. can also include an aliphatic hydroxycarboxylic acid; satd. alkanol; amine, and at least one of sucrose, glucose and fructose. The proportion of malodorous (I) needed and no HCN is evolved. The waving treatment is completed in a shorter time, and can be carried out immediately after dyeing the hair without adverse effect on the colour.
Part A is a dose escalation study in up to 4 cohorts of patients designed to test the safety and efficacy of DSP107 administered alone and in combination with AZA. The DSP107 starting dose level in Part A will be 0.3 mg/kg based on aggregate safety, PK and PD data from study DSP107_001, an ongoing study exploring the safety of escalating DSP107 doses in patients with advanced solid tumors. There will be a single DLT evaluation period, lasting 28 days, to determine the safety of DSP107 in combination with AZA. The safety, efficacy and PK data will be used to establish a recommended Phase II dose for potential future expansion cohorts and a starting dose for Part B.

Part B is a dose escalation study in 2 cohorts of patients that will test the safety and efficacy of DSP107 in combination with AZA and VEN. The starting dose for Part B will be at least one dose level lower than the DSP107 dose selected in Part A as being safe and effective in combination with AZA. Once a safe, effective dose has been established in Part B, a recommended phase 2 dose for patients with newly diagnosed AML will be agreed with the FDA at an End-of-Phase 1 meeting.
Disclosed is a medicament comprising: (a) an immunogen or immunogenic hapten-carrier conjugate, wherein the immunogen or hapten is recognised by an endogenous antibody in the host or is recognised directly by an immune cell in the host, and wherein the hapten is an unnatural hapten; and (b) a TH1-biasing adjuvant. Such compositions are useful for enhancing in endogenous immune response-mediated specific elimination of a population of pathogenic cells in a preimmunized host animal harboring the population, wherein members of the cell population have an accessible binding site for a ligand. The composition is particularly useful for treating disease states characterized by the existence of pathogenic cell populations. In accordance with the described method, cell-targeted ligand-immunogen or ligand-hapten complexes are administered to a diseased host to redirect the host immune response to the pathogenic cells which have an accessible binding site for the ligand. The improvement to the method comprises the step of using a TH1-biasing adjuvant to enhance the immune response to cell-bound ligand-immunogen or ligand-hapten conjugates. Specifically disclosed is a use of (a) an immunogenic hapten-carrier conjugate; and (b) a TH1-biasing adjuvant for preparation of a medicament for enhancing an endogenous immune response-mediated specific elimination of a population of pathogenic cells in a host animal harboring the population, wherein the hapten is an unnatural hapten, and wherein the hapten is recognized by an endogenous antibody in the host or is recognized directly by an immune cell in the host; wherein said medicament is formulated for simultaneous or sequential administration of said conjugate and said TH1-biasing adjuvant. Also disclosed is a use of (a) a TH1-biasing adjuvant; and (b) a ligand-hapten conjugate for preparation of a medicament for enhancing an immune response in a host animal harboring a population of pathogenic cells to eliminate said pathogenic cell population wherein the pathogenic cells have an accessible binding site for the ligand; wherein said medicament is formulated for simultaneous or sequential administration of said conjugate and said TH1-biasing adjuvant.
The patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 gin 250 mLof water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded.
Methods, systems and apparatus for the tracking and managing of biological samples. A provider may check-in or register a patient at a provider facility. A sample tube may be registered to the patient, and a biological sample may be collected. The provider aggregates a plurality of sample tubes into cells of a rack. The provider then captures an image of the rack. A computer vision operation may be performed to isolate and identify a QR code affixed to the lid of each sample tube. The identified sample tubes are registered to the rack in which they are held, and the rack transferred to a destination lab. The same computer vision operation may be performed upon receipt of the rack. The samples may then be transferred to a sample plate. The samples are transferred from a cell in the rack to a corresponding well in the sample plate.
A method for producing a retrievable hairstyling using shape memory polymers is described. Here a composition is applied to the hair, said composition containing a shape memory polymer P or a macromer M that can be cross-linked to a shape memory polymer, the hair is arranged into a given (permanent) shape and said permanent shape is then fixed by means of chemical cross-linking of the macromer M under the formation of a shape memory polymer and/or under physical cross-linking of the polymer P. The polymer P and the macromer M are formed from block copolymers, each of which comprises at least a first block and at least two additional blocks. The first block is a polyol and is selected from polyethers, dimerdiol and derivatives derived therefrom, as well as from polyesters of dicarboxylic acids with diols. The additional blocks are polyesters of hydroxycarboxylic acids or their lactones. The macromer M possesses cross-linkable regions, as well as thermoplastic regions that are not cross-linkable and, after cross-linking, has a transition temperature of T<SUB>trans</SUB>. The polymer P has a hard segment with a first transition temperature T'<SUB>trans</SUB>, which is above room temperature, and a soft segment with a second transition temperature T<SUB>trans </SUB>which is lower than T'<SUB>trans</SUB>.
INTRODUCTION: Circulating tissue transglutaminase immunoglobulin A concentration is a sensitive and specific indicator of celiac disease, but discrepancies between serologic and histologic findings occur. We hypothesized that fecal markers of inflammation and protein loss would be greater in patients with untreated celiac disease than in healthy controls. Our study aims to evaluate multiple fecal and plasma markers in celiac disease and correlate these findings with serologic and histologic findings as noninvasive means of evaluating disease activity.
METHODS: Participants with positive celiac serologies and controls with negative celiac serologies were prospectively enrolled before upper endoscopy. Blood, stool, and duodenal biopsies were collected. Concentrations of fecal lipocalin-2, calprotectin, and alpha-1-antitrypsin and plasma lipocalin-2 were determined. Biopsies underwent modified Marsh scoring. Significance was tested between cases and controls, modified Marsh score and tissue transglutaminase immunoglobulin A concentration.
RESULTS: Lipocalin-2 was significantly elevated in the stool ( P = 0.006) but not the plasma of participants with positive celiac serologies. There was no significant difference in fecal calprotectin or alpha-1 antitrypsin between participants with positive celiac serologies and controls. Fecal alpha-1 antitrypsin >100 mg/dL was specific, but not sensitive for biopsy-proven celiac disease.
DISCUSSION: Lipocalin-2 is elevated in the stool but not the plasma of patients with celiac disease suggesting a role of local inflammatory response. Calprotectin was not a useful marker in the diagnosis of celiac disease. While random fecal alpha-1 antitrypsin was not significantly elevated in cases compared with controls, an elevation of greater than 100 mg/dL was 90% specific for biopsy-proven celiac disease.
A culture medium is used for culturing neural cells. Each neural cell includes a neural cell body and at least one neurite branched from the neural cell body. The culture medium includes a substrate and a carbon nanotube structure located on the substrate. The carbon nanotube structure includes a number of carbon nanotube wires spaced apart from each other. A distance between adjacent carbon nanotube wires is greater than or equal to diameters of the neural cell bodies. The carbon nanotube wires are capable of guiding extending directions of the neurites.